Abdominal Bloating: Pathophysiology and Treatment
Pharmacol 1974;14:617-623.
154. Holtmann G, Gschossmann J, Mayr P, Talley NJ. A randomized
placebo-controlled trial of simethicone and cisapride for the treat-
ment of patients with functional dyspepsia. Aliment Pharmacol
Ther 2002;16:1641-1648.
155. Lecuyer M, Cousin T, Monnot MN, Coffin B. Efficacy of an acti-
vated charcoal-simethicone combination in dyspeptic syndrome: re-
sults of a randomized prospective study in general practice.
Gastroenterol Clin Biol 2009;33:478-484.
156. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride chan-
nel activator, in adult patients with chronic constipation: a dou-
ble-blind, placebo-controlled, dose - ranging study to evaluate effi-
cacy and safety. Aliment Pharmacol Ther 2007;25:1351-1361.
157. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubi-
prostone in patients with constipation-associated irritable bowel syn-
drome-results of two randomized, placebo-controlled studies.
Aliment Pharmacol Ther 2009;29:329-341.
158. Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials:
linaclotide phase 3 studies in IBS-C - a prespecified further analysis
based on European Medicines Agency-specified endpoints. Ali-
ment Pharmacol Ther 2013;37:49-61.
159. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of
linaclotide for chronic constipation. N Engl J Med 2011;365:
527-536.
160. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin
reuptake inhibitor fluoxetine does not change rectal sensitivity and
symptoms in patients with irritable bowel syndrome: a double blind,
randomized, placebo-controlled study. Clin Gastroenterol Hepatol
2003;1:219-228.
161. Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G.
Paroxetine to treat irritable bowel syndrome not responding to
high-fiber diet: a double-blind, placebo-controlled trial. Am J
Gastroenterol 2004;99:914-920.
162. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM,
Janssens J. A controlled crossover study of the selective serotonin re-
uptake inhibitor citalopram in irritable bowel syndrome. Gut
2006;55:1095-1103.
163. Corazziari E. Role of opioid ligands in the irritable bowel syndrome.
Can J Gastroenterol 1999;13(suppl A):71A-75A.
164. Fraitag B, Homerin M, Hecketsweiler P. Double-blind dose-re-
sponse multicenter comparison of fedotozine and placebo in treat-
ment of nonulcer dyspepsia. Dig Dis Sci 1994;39:1072-1077.
165. Mangel A, Bornstein J, Hamm L, et al. Clinical trial: asimadoline
in the treatment of patients with irritable bowel syndrome. Aliment
Pharmacol Ther 2008;28:239-249.
166. Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB,
Thomas GA. Naloxone treatment for irritable bowel syndrome - a
Vol. 19, No. 4 October, 2013 (433-453)
randomized controlled trial with an oral formulation. Aliment
Pharmacol Ther 2002;16:1649-1654.
167. Camilleri M. Current and future pharmacological treatments for di-
arrhea-predominant irritable bowel syndrome. Expert Opin Phar-
macother 2013;14:1151-1160.
168. Simrén M. Bloating and abdominal distention: not so poorly under-
stood anymore! Gastroenterology 2009;136:1487-1490.
169. Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA. Tegaserod
for female patients suffering from IBS with mixed bowel habits or
constipation: a randomized controlled trial. Am J Gastroenterol
2008;103:1217-1225.
170. George AM, Meyers NL, Hickling RI. Clinical trial: renzapride
therapy for constipation-predominant irritable bowel syndrome -
multicentre, randomized, placebo-controlled, double-blind study in
primary healthcare setting. Aliment Pharmacol Ther 2008;27:
830-837.
171. Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Longterm treatment
of irritable bowel syndrome with cimetropium bromide: a double
blind placebo controlled clinical trial. Gut 1990;31:355-358.
172. Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW.
Alverine citrate fails to relieve the symptoms of irritable bowel syn-
drome: results of a double-blind, randomized, placebo-controlled
trial. Aliment Pharmacol Ther 2002;16:1187-1195.
173. Chang FY, Lu CL, Luo JC, Chen TS, Chen MJ, Chang HJ. The
evaluation of otilonium bromide treatment in asian patients with irri-
table bowel syndrome. J Neurogastroenterol Motil 2011;17:
402-410.
174. Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Dele-
strain MC. Clinical trial: the efficacy of alverine citrate/simeticone
combination on abdominal pain/discomfort in irritable bowel syn-
drome - a randomized, double-blind, placebo-controlled study.
Aliment Pharmacol Ther 2010;31:615-624.
175. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R.
The effect of fluoxetine in patients with pain and constipation-pre-
dominant irritable bowel syndrome: a double-blind randomized-
controlled study. Aliment Pharmacol Ther 2005;22:381-385.
176. Vahedi H, Merat S, Momtahen S, et al. Clinical trial: the effect of
amitriptyline in patients with diarrhoea-predominant irritable bowel
syndrome. Aliment Pharmacol Ther 2008;27:678-684.
177. Read NW, Abitbol JL, Bardhan KD, Whorwell PJ, Fraitag B.
Efficacy and safety of the peripheral kappa agonist fedotozine versus
placebo in the treatment of functional dyspepsia. Gut 1997;41:
664-668.
178. Szarka LA, Camilleri M, Burton D, et al. Efficacy of on-demand
asimadoline, a peripheral kappa-opioid agonist, in females with irri-
table bowel syndrome. Clin Gastroenterol Hepatol 2007;5:1268-
1275.
453